n-14-42.pdf

Preserve advance releases and the authoritative Internal Revenue Bulletin rendition; directory timestamps are file-publication metadata, not legal effective dates. HTML bulletins begin June 2003; earlier available issues require full PDF parsing.

This collection currently includes the publisher’s available advance-release directory. Historical bulletin renditions are discovered separately; an advance-release record alone does not certify the collection archive complete.

Part III – Administrative, Procedural, and Miscellaneous

Branded Prescription Drug Fee; Procedural and Administrative Guidance

Notice 2014-42

Purpose
This notice provides guidance on the branded prescription drug fee for each fee
year related to (1) the submission of Form 8947, “Report of Branded Prescription Drug
Information,” (2) the time and manner for notifying covered entities of their preliminary
fee calculation, (3) the time and manner for submitting error reports for the dispute
resolution process, and (4) the time for notifying covered entities of their final fee
calculation.
Background
An annual fee on covered entities engaged in the business of manufacturing or
importing branded prescription drugs is imposed by § 9008 of the Patient Protection and
Affordable Care Act, Public Law 111-148 (124 Stat. 119 (2010)), as amended by § 1404
of the Health Care and Education Reconciliation Act of 2010, Public Law 111-152 (124
Stat. 1029 (2010)) (collectively the ACA).

2
The Branded Prescription Drug Fee Regulations in 26 C.F.R. Part 51, which
were published on July 24, 2014, (TD 9684) provide the method by which each covered
entity’s annual fee is calculated. These regulations also define terms for the
administration of the fee. As relevant for this notice, § 51.2(g) defines fee year as the
calendar year in which the fee for a particular sales year must be paid and § 51.2(m)
defines sales year as the second calendar year preceding the fee year.
Section 51.3 provides that annually, each covered entity may submit a completed
Form 8947, “Report of Branded Prescription Drug Information,” in accordance with the
instructions for the form. Generally, the form solicits information from covered entities
on National Drug Codes, orphan drugs, designated entities, rebates, and other
information specified by the form or its instructions. The form is to be filed by the date
prescribed in guidance published in the Internal Revenue Bulletin.
Section 51.6 provides that for each sales year the Internal Revenue Service
(IRS) will make a preliminary fee calculation for each covered entity and will notify each
covered entity of this calculation by the date prescribed in guidance published in the
Internal Revenue Bulletin. This notification will also include additional prescribed
information. As used in this notice, “notice of preliminary fee calculation” includes the
additional prescribed information.
Section 51.7 provides that upon receipt of its preliminary fee calculation, each
covered entity will have an opportunity to dispute this calculation by submitting to the
IRS an error report with prescribed information. Sections 51.7(b) and (c) set out the
information that a covered entity must submit to support each asserted error. Section

3
51.7(d) provides that each covered entity must submit its error report(s) in the form and
manner that is prescribed in guidance published in the Internal Revenue Bulletin. This
guidance will also prescribe the date by which each covered entity must submit its
report(s).
Section 51.8 provides that the IRS will send each covered entity its final fee
calculation no later than August 31 of each fee year and also provides that covered
entities must pay their fee by September 30 of the fee year.
Section 7503 of the Internal Revenue Code provides that if the last day for
performing an act required under the authority of the internal revenue laws falls on a
Saturday, Sunday, or legal holiday, the performance of the act is timely if the act is
performed on the next succeeding day that is not a Saturday, Sunday, or legal holiday.
Section 9008(f)(1) of the ACA and § 51.9(a) treat this annual fee as an excise tax for
purposes of subtitle F of the Code. Therefore, § 7503 applies to acts required to be
performed under § 9008. Accordingly, if a date prescribed in this notice falls on a
Saturday, Sunday, or legal holiday, a covered entity’s performance of an act by this date
is timely if the covered entity performs the act on the next succeeding day that is not a
Saturday, Sunday, or legal holiday.
Submission of Form 8947
For each fee year, a covered entity that chooses to submit Form 8947 reporting
information for the sales year must file the form by November 1 of the preceding year. .
For example, for the 2015 fee year, a covered entity must submit its Form 8947

4
reporting information for the 2013 sales year by Monday, November 3, 2014 (after
applying § 7503). .
A covered entity may submit its Form 8947 by mail or using e-file. Before using
e-file, a covered entity must first: (1) successfully register with IRS e-services; (2)
successfully complete the e-file application; and (3) receive an e-file acceptance letter
(5120C letter) that contains an Electronic Filing Identification Number (EFIN) and an
Electronic Transmitter Identification Number (ETIN). A covered entity must also file
Form 8453-R, Declaration and Signature for Electronic Filing of Forms 8947 and 8963.
The IRS provides instructions regarding e-file on the dedicated ACA e-file webpage at
http://www.irs.gov/uac/e-file-Affordable-Care-Act-Information-Reports. A covered entity
may also contact the IRS e-Help Desk at 1-866-937-4130 (Monday through Friday from
6:30 am to 6:00 pm (CST)).
Time and manner for notifying covered entities of their preliminary fee calculation
The IRS will mail each covered entity a paper notice of its preliminary fee
calculation by March 1 of each fee year. This mailing will include a National Drug Code
attachment (NDC attachment) that lists the covered entity’s National Drug Codes and
the sales data reported to the IRS by each government program pursuant to § 51.4.
A covered entity may request that the IRS send an electronic copy of the NDC
attachment on a separate CD-ROM in Microsoft Excel format or other electronic format
the IRS may designate in the future. The covered entity must submit a request by
February 15 of each fee year by telephone, email, or fax as indicated in the Contact
Information section of this notice. If a covered entity makes this request timely, the IRS

5
will mail the covered entity its notice of preliminary fee calculation and the NDC
attachment on paper as well as send the electronic version of the NDC attachment by
March 1 of each fee year.
Time and manner for submitting error reports for the dispute resolution process
A covered entity that chooses to submit an error report regarding its preliminary
fee calculation must mail the error report by May 15 of each fee year.
When the IRS mails each covered entity a notice of its preliminary fee calculation
by March 1 of each fee year, the IRS will also send each covered entity a template that
the covered entity must use to prepare its error report. The IRS will send this template
on a separate CD-ROM in Microsoft Excel format or other electronic format the IRS may
designate in the future. All completed templates and the supporting documentation
must be submitted on a CD-ROM in Microsoft Excel format or other electronic format
designated by the IRS and sent to:
Department of the Treasury
Internal Revenue Service – Branded Prescription Drug Fee
1973 N. Rulon White Boulevard, Mail Stop 4916
Ogden, UT 84404
Notice of Final Fee Calculation
In accordance with § 51.8(a), the IRS will notify each covered entity of its final fee
calculation by August 31 of each fee year. The IRS will mail a notice of final fee
calculation and a final NDC attachment on paper. If, for purposes of the preliminary fee
notification, a covered entity timely requested that the IRS send an electronic copy of

6
the NDC attachment on a separate CD-ROM or other electronic format, the IRS will also
send an electronic copy of the final NDC attachment on a separate CD-ROM or other
electronic format. In accordance with § 51.8(c), each covered entity must pay this fee
by September 30 of each fee year.
Contact Information
A covered entity may contact the IRS regarding the branded prescription drug fee
by: (1) leaving a voice mail message in the BPD Mailbox at (908) 301-2118 (not a toll
free call); (2) sending an email to it.bpd.fee@irs.gov; or (3) sending a fax toll free to
(877) 797-0234.
Effective/Applicability Date
This Notice is effective on August 11, 2014, and applies on October 1, 2014 and
thereafter.
Effect on Other Documents
Notice 2013-51, 2013-34 I.R.B. 153, which provides guidance for the 2014 fee
year, is obsoleted as of October 1, 2014.
Drafting Information
The principal author of this notice is Celia Gabrysh of the Office of Associate
Chief Counsel (Passthroughs & Special Industries). For further information regarding
this notice, please contact Celia Gabrysh at (202) 317-6855 (not a toll-free call).